With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
Executive Summary
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
You may also be interested in...
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.
Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field
Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.
How Immuno-Oncology Is Turning Biomarker Development On Its Head
Immuno-oncology’s challenge is to orchestrate a biomarker program in a highly competitive drug development landscape knowing that prior to having significant clinical experience, the program is unlikely to yield the kinds of binary measurements used to define and select a patient population for a targeted therapy.